<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999401</url>
  </required_header>
  <id_info>
    <org_study_id>CYC682-07</org_study_id>
    <nct_id>NCT00999401</nct_id>
  </id_info>
  <brief_title>A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyclacel Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyclacel Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the maximum tolerated dose (MTD) or
      recommended phase II doses of sapacitabine and seliciclib administered sequentially or
      concomitantly. The secondary objectives are to evaluate antitumor activity of this
      sequential or concomitant treatment and to explore the pharmacodynamic effect of this
      treatment in skin and peripheral blood mononuclear cells.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>maximum tolerated dose</measure>
    <time_frame>1-3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumor response rate</measure>
    <time_frame>1-3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic effects in skin and peripheral mononuclear cells</measure>
    <time_frame>1-3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>sapacitabine and seliciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential or concomitant administration of sapacitabine and seliciclib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sapacitabine and seliciclib</intervention_name>
    <description>sequential or concomitant administration of sapacitabine and seliciclib</description>
    <arm_group_label>sapacitabine and seliciclib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Incurable advanced solid tumors that are no longer responding to conventional therapy
             or for which no effective therapy exists; at the RD of Part 1, an extension cohort up
             to 20 patients with metastatic breast cancer who are known to be BRCA mutation
             carriers will be enrolled.

          -  Age 18 years or older

          -  ECOG 0-2

          -  Life expectancy â‰¥ 3 months

          -  Evaluable disease

          -  Adequate bone marrow function

          -  Adequate renal function

          -  Adequate liver function

          -  At least 3 weeks from prior systemic treatments including investigational anti-cancer
             therapy, radiation therapy; and have recovered from prior toxicities

          -  Able to swallow capsules

          -  At least 3 weeks from major surgery

          -  Agree to practice effective contraception

          -  Ability to understand and willingness to sign the informed consent form

        Exclusion Criteria:

          -  Previously untreated CNS metastases or progressive CNS metastases

          -  Currently receiving radiotherapy, biological therapy, or any other investigational
             agents

          -  Uncontrolled intercurrent illness including

          -  Pregnant or lactating women

          -  Known to be HIV-positive

          -  A history of active hepatitis B and/or hepatitis C infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey Shapiro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sara Tolaney, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey Shapiro, M.D.</last_name>
      <phone>617-632-4942</phone>
    </contact>
    <contact_backup>
      <last_name>Tracy Bell, R.N.</last_name>
      <phone>617.632.3482</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Tolaney, M.D.</last_name>
      <phone>617-632-2335</phone>
    </contact>
    <contact_backup>
      <last_name>Leilani Anderson, RN</last_name>
      <phone>617-632-3129</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-202.short</url>
    <description>Responses to sequential sapacitabine and seliciclib in patients with BRCA-deficient solid tumors</description>
  </link>
  <results_reference>
    <citation>Shapiro GI, et al. Responses to sequential sapacitabine and seliciclib in patients with BRCA-deficient solid tumors. Cancer Res April 15, 2013 73; LB-202.</citation>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>May 2, 2016</lastchanged_date>
  <firstreceived_date>October 19, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Roscovitine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
